Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rhythm Pharma nets $162mm via FOPO

Executive Summary

Rhythm Pharmaceuticals Inc. (developing therapies for rare genetic disorders of obesity) netted $162.1mm through the follow-on public offering of 9.32mm common shares (including full exercise of the overallotment) at $18.50 each. The company plans to use some of the proceeds for clinical trials, translational research and genotyping, and to submit regulatory filings as it prepares to commercialize setmelanotide.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies